Clinical utility of the dexamethasone suppression test assessed by plasma and salivary cortisol determinations

N. Cook,B. Harris,R. Walker,R. Hailwood,Emyr Jones,S. Johns,D. Riad-fahmy

DOI: https://doi.org/10.1016/0165-1781(86)90026-0

IF: 11.3

1986-06-01

Psychiatry Research

Abstract:

What problem does this paper attempt to address?

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

Abdullah Alsultan,Charles A. Peloquin

DOI: https://doi.org/10.1007/s40265-014-0222-8

2014-05-21

Drugs

Abstract:Tuberculosis (TB) is the world’s second leading infectious killer. Cases of multidrug-resistant (MDR-TB) and extremely drug-resistant (XDR-TB) have increased globally. Therapeutic drug monitoring (TDM) remains a standard clinical technique for using plasma drug concentrations to determine dose. For TB patients, TDM provides objective information for the clinician to make informed dosing decisions. Some patients are slow to respond to treatment, and TDM can shorten the time to response and to treatment completion. Normal plasma concentration ranges for the TB drugs have been defined. For practical reasons, only one or two samples are collected post-dose. A 2-h post-dose sample approximates the peak serum drug concentration (Cmax) for most TB drugs. Adding a 6-h sample allows the clinician to distinguish between delayed absorption and malabsorption. TDM requires that samples are promptly centrifuged, and that the serum is promptly harvested and frozen. Isoniazid and ethionamide, in particular, are not stable in human serum at room temperature. Rifampicin is stable for more than 6 h under these conditions. Since our 2002 review, several papers regarding TB drug pharmacokinetics, pharmacodynamics, and TDM have been published. Thus, we have better information regarding the concentrations required for effective TB therapy. In vitro and animal model data clearly show concentration responses for most TB drugs. Recent studies emphasize the importance of rifamycins and pyrazinamide as sterilizing agents. A strong argument can be made for maximizing patient exposure to these drugs, short of toxicity. Further, the very concept behind ‘minimal inhibitory concentration’ (MIC) implies that one should achieve concentrations above the minimum in order to maximize response. Some, but not all clinical data are consistent with the utility of this approach. The low ends of the TB drug normal ranges set reasonable ‘floors’ above which plasma concentrations should be maintained. Patients with diabetes and those infected with HIV have a particular risk for poor drug absorption, and for drug–drug interactions. Published guidelines typically describe interactions between two drugs, whereas the clinical situation often is considerably more complex. Under ‘real–life’ circumstances, TDM often is the best available tool for sorting out these multi-drug interactions, and for providing the patient safe and adequate doses. Plasma concentrations cannot explain all of the variability in patient responses to TB treatment, and cannot guarantee patient outcomes. However, combined with clinical and bacteriological data, TDM can be a decisive tool, allowing clinicians to successfully treat even the most complicated TB patients.

pharmacology & pharmacy,toxicology
Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections

Jan-Willem Alffenaar,Anne-Grete Märtson,Scott K. Heysell,Jin-Gun Cho,Asad Patanwala,Gina Burch,Hannah Y. Kim,Marieke G. G. Sturkenboom,Anthony Byrne,Debbie Marriott,Indy Sandaradura,Simon Tiberi,Vitali Sintchencko,Shashikant Srivastava,Charles A. Peloquin

DOI: https://doi.org/10.1007/s40262-021-01000-6

2021-03-10

Clinical Pharmacokinetics

Abstract:Nontuberculous mycobacteria can cause minimally symptomatic self-limiting infections to progressive and life-threatening disease of multiple organs. Several factors such as increased testing and prevalence have made this an emerging infectious disease. Multiple guidelines have been published to guide therapy, which remains difficult owing to the complexity of therapy, the potential for acquired resistance, the toxicity of treatment, and a high treatment failure rate. Given the long duration of therapy, complex multi-drug treatment regimens, and the risk of drug toxicity, therapeutic drug monitoring is an excellent method to optimize treatment. However, currently, there is little available guidance on therapeutic drug monitoring for this condition. The aim of this review is to provide information on the pharmacokinetic/pharmacodynamic targets for individual drugs used in the treatment of nontuberculous mycobacteria disease. Lacking data from randomized controlled trials, in vitro, in vivo, and clinical data were aggregated to facilitate recommendations for therapeutic drug monitoring to improve efficacy and reduce toxicity.

pharmacology & pharmacy
Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009-2014

Scott K. Heysell,Jane L. Moore,Charles A. Peloquin,David Ashkin,Eric R. Houpt

DOI: https://doi.org/10.4046/trd.2015.78.2.78

2015-01-01

Tuberculosis and Respiratory Diseases

Abstract:BACKGROUND: Reports of therapeutic drug monitoring (TDM) for second-line medications to treat multidrug-resistant tuberculosis (MDR-TB) remain limited.METHODS: A retrospective cohort from the Virginia state tuberculosis (TB) registry, 2009-2014, was analyzed for TDM usage in MDR-TB. Drug concentrations, measured at time of estimated peak (Cmax), were compared to expected ranges.RESULTS: Of 10 patients with MDR-TB, 8 (80%) had TDM for at least one drug (maximum 6 drugs). Second-line drugs tested were cycloserine in seven patients (mean C2hr, 16.6±10.2 µg/mL; 4 [57%] below expected range); moxifloxacin in five (mean C2hr, 3.2±1.5 µg/mL; 1 [20%] below); capreomycin in five (mean C2hr, 21.5±14.0 µg/mL; 3 [60%] below); para-aminosalicylic acid in five (mean C6hr, 65.0±29.1 µg/mL; all within or above); linezolid in three (mean C2hr, 11.4±4.1 µg/mL, 1 [33%] below); amikacin in two (mean C2hr, 35.3±3.7 µg/mL; 1 [50%] below); ethionamide in one (C2hr, 1.49 µg/mL, within expected). Two patients died: a 38-year-old woman with human immunodeficiency virus/acquired immune deficiency syndrome and TB meningitis without TDM, and a 76-year-old man with fluoroquinolone-resistant (pre-extensively drug-resistant) pulmonary TB and low linezolid and capreomycin concentrations.CONCLUSION: Individual pharmacokinetic variability was common. A more standardized approach to TDM for MDR-TB may limit over-testing and maximize therapeutic gain.
Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management

Nguyen Quang Thu,Nguyen Tran Nam Tien,Nguyen Thi Hai Yen,Thuc-Huy Duong,Nguyen Phuoc Long,Huy Truong Nguyen

DOI: https://doi.org/10.1016/j.jpha.2023.09.009

Abstract:The spread of tuberculosis (TB), especially multidrug-resistant TB and extensively drug-resistant TB, has strongly motivated the research and development of new anti-TB drugs. New strategies to facilitate drug combinations, including pharmacokinetics-guided dose optimization and toxicology studies of first- and second-line anti-TB drugs have also been introduced and recommended. Liquid chromatography-mass spectrometry (LC-MS) has arguably become the gold standard in the analysis of both endo- and exo-genous compounds. This technique has been applied successfully not only for therapeutic drug monitoring (TDM) but also for pharmacometabolomics analysis. TDM improves the effectiveness of treatment, reduces adverse drug reactions, and the likelihood of drug resistance development in TB patients by determining dosage regimens that produce concentrations within the therapeutic target window. Based on TDM, the dose would be optimized individually to achieve favorable outcomes. Pharmacometabolomics is essential in generating and validating hypotheses regarding the metabolism of anti-TB drugs, aiding in the discovery of potential biomarkers for TB diagnostics, treatment monitoring, and outcome evaluation. This article highlighted the current progresses in TDM of anti-TB drugs based on LC-MS bioassay in the last two decades. Besides, we discussed the advantages and disadvantages of this technique in practical use. The pressing need for non-invasive sampling approaches and stability studies of anti-TB drugs was highlighted. Lastly, we provided perspectives on the prospects of combining LC-MS-based TDM and pharmacometabolomics with other advanced strategies (pharmacometrics, drug and vaccine developments, machine learning/artificial intelligence, among others) to encapsulate in an all-inclusive approach to improve treatment outcomes of TB patients.
Understanding Therapeutic drug monitoring (TDM) at a glance

Abdullah Al Noman,Anupama Chakraborty,Honufa Akter,Raisa Mustafa Binti

DOI: https://doi.org/10.22161/ijmpd.7.1.1

2023-01-01

Abstract:This paper gives an overview of therapeutic drug monitoring. The primary objectives of TDM are to prevent therapeutic failures carried on by poor compliance or prescribing a drug at a dose that is too low, as well as negative or toxic effects brought on by an excessive dose. Moreover, it gives information about when and what type of drug needs therapeutic drug monitoring. Like the drug which has a short therapeutic window they require therapeutic monitoring because it can cause toxicity or no therapeutic effect. However, the appropriate use of TDM is not only the simple measurement of patient blood drug concentration and the comparison of its target range but also TDM plays an important role in the therapeutic medication by ensuring safety and effectiveness also with individualization of these medications, desired clinical targets, dosage history, sampling time in relation to the dose patient’s response these factors needed to be considered while interpreting drug concentration measurements to achieve the optimal response with minimal toxicity. So TDM can be considered as a combined approach encompassing pharmaceutical, pharmacokinetic, pharmacodynamic techniques and analyses.
Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review

Prakruti S. Rao,Nisha Modi,Nam-Tien Tran Nguyen,Dinh Hoa Vu,Yingda L. Xie,Monica Gandhi,Roy Gerona,John Metcalfe,Scott K. Heysell,Jan-Willem C. Alffenaar

DOI: https://doi.org/10.1007/s40262-023-01220-y

2023-03-05

Clinical Pharmacokinetics

Abstract:Quantifying exposure to drugs for personalized dose adjustment is of critical importance in patients with tuberculosis who may be at risk of treatment failure or toxicity due to individual variability in pharmacokinetics. Traditionally, serum or plasma samples have been used for drug monitoring, which only poses collection and logistical challenges in high-tuberculosis burden/low-resourced areas. Less invasive and lower cost tests using alternative biomatrices other than serum or plasma may improve the feasibility of therapeutic drug monitoring.

pharmacology & pharmacy
The past, present and future of tuberculosis treatment.

Kefan Bi,Dan Cao,Cheng Ding,Shuihua Lu,Hongzhou Lu,Guangyu Zhang,Wenhong Zhang,Liang Li,Kaijin Xu,Lanjuan Li,Ying Zhang

DOI: https://doi.org/10.3724/zdxbyxb-2022-0454

2023-01-01

Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.
Manometer extension for high pressure measurement: nuclear quadrupole resonance study of Cu2O with a modified Bridgman anvil cell up to 10 GPa.

H. Fukazawa,N. Yamatoji,Y. Kohori,C. Terakura,Nao Takeshita,Y. Tokura,H. Takagi

DOI: https://doi.org/10.1063/1.2426875

IF: 1.6

2007-01-17

Review of Scientific Instruments

Abstract:We report (63)Cu nuclear quadrupole resonance (NQR) measurement of Cu(2)O under pressure up to about 10 GPa at low temperatures. Because the lattice parameter of Cu(2)O changes with increasing pressure, the electric field gradient at the Cu site also changes correspondingly with pressure. This enables us to use the Cu(2)O as an in situ manometer for high pressure nuclear magnetic resonance/NQR up to about 9 GPa.
A guide to therapeutic drug monitoring of β‐lactam antibiotics

Andrew J. Fratoni,David P. Nicolau,Joseph L. Kuti

DOI: https://doi.org/10.1002/phar.2505

2021-02-01

Abstract:Therapeutic drug monitoring (TDM) opens the door to personalized medicine, yet it is infrequently applied to β‐lactam antibiotics, one of the most commonly prescribed drug classes in the hospital setting. As we continue to understand more about β‐lactam pharmacodynamics (PD) and wide inter‐ and intra‐patient variability in pharmacokinetics (PK), the utility of TDM has become increasingly apparent. For β‐lactams, the time that free concentrations remain above the minimum inhibitory concentration (MIC) as a function of the dosing interval (%fT>MIC) has been shown to best predict antibacterial effect. Many studies have shown that β‐lactam %fT>MIC exposures are often suboptimal across a wide variety of disease states and clinical settings. A limitation to implementing this practice is the general lack of understanding on how to best operationalize this intervention and interpret the results. The instrumentation and expertise needed to quantify β‐lactams for TDM is rarely available locally, but certain laboratories advertise these services and perform them regularly. Familiarity with the modalities and nuances of antimicrobial susceptibility testing is crucial to establishing β‐lactam concentration targets that meet the relevant exposure thresholds. Evaluation of these concentrations is best accomplished using population PK software and Bayesian modeling, for which a multitude of programs are available. While TDM of β‐lactams has shown an ability to increase the rate of target attainment, there is currently limited evidence to suggest that it leads to improved clinical outcomes. Although consensus guidelines for β‐lactam TDM do not exist in the United States, guidance would help to promote this important practice and better standardize the approach across institutions. Herein, we discuss the basis for β‐lactam TDM, review supporting evidence, and provide guidance for implementation in specific patient populations.
[Low-dose weekly paclitaxel therapy proved useful for a case of recurrent gastric cancer with clinically latent hepatic cirrhosis].

R. Yamada,T. Ohshima,Tsutomu Sato,Y. Ohtsuka,C. Kunisaki,T. Imada

Abstract:The patient was a 68-year-old-man who suffered from recurrent peritoneal gastric cancer. He was initially treated with TS-1 as an outpatient. However, his serum CEA level elevated in March 2004, and he complained of epigastric pain in June. A chest and abdominal CT revealed lung and local recurrence. He began weekly paclitaxel as second-line chemotherapy in September. Paclitaxel was infused once a week for two weeks as one cycle, at a dose of 60 mg because of the clinically latent hepatic cirrhosis. One month after the first infusion therapy, epigastric pain was greatly reduced. A CT scan showed the lung metastasis had disappeared and the size of the tumor around the anastomosis was reduced to 50% after 2 months. The toxic events were appetite loss (grade 2) and alopecia (grade 2).
Fixed-dose Combination and Therapeutic Drug Monitoring in Tuberculosis: Friend or Foe?

Marlanka A Zuur,Onno W Akkerman,Lina Davies Forsman,Yi Hu,Rongdong Zheng,Judith Bruchfeld,Simon Tiberi,Giovanni Battista Migliori,Jan-Willem C Alffenaar

DOI: https://doi.org/10.1183/13993003.00833-2016

2016-01-01

Abstract:Tuberculosis (TB) remains one of the world's deadliest infectious diseases. The World Health Organization (WHO) estimated that, in 2014 alone, 9.6 million people fell ill with TB and 1.5 million died due to the disease [1]. South-East Asia and Western Pacific Regions accounted for 58% of these [1]. As most deaths from TB can now be prevented, efforts must be accelerated to ensure the targets of the Sustainable Development Goals are reached [1]. Fixed-dose combination and therapeutic drug monitoring can be combined in programmatic treatment of tuberculosis http://ow.ly/sCtd302h0Ka
Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy

Eman Wehbe,Asad E. Patanwala,Christine Y. Lu,Hannah Yejin Kim,Sophie L. Stocker,Jan-Willem C. Alffenaar

DOI: https://doi.org/10.3390/pharmaceutics16050677

IF: 6.525

2024-05-18

Pharmaceutics

Abstract:Due to variability in pharmacokinetics and pharmacodynamics, clinical outcomes of antimicrobial drug therapy vary between patients. As such, personalised medication management, considering both pharmacokinetics and pharmacodynamics, is a growing concept of interest in the field of infectious diseases. Therapeutic drug monitoring is used to adjust and individualise drug regimens until predefined pharmacokinetic exposure targets are achieved. Minimum inhibitory concentration (drug susceptibility) is the best available pharmacodynamic parameter but is associated with many limitations. Identification of other pharmacodynamic parameters is necessary. Repurposing diagnostic biomarkers as pharmacodynamic parameters to evaluate treatment response is attractive. When combined with therapeutic drug monitoring, it could facilitate making more informed dosing decisions. We believe the approach has potential and justifies further research.

pharmacology & pharmacy
Drug targets, current and future therapeutics for the treatment of multi drug resistant tuberculosis with their clinical applications: A critical review

Deepshikha Singh,Vikram Singh,Subhankar P. Mandal,Karen Dsouza,B. R. Prashantha Kumar,Sheshagiri Dixit

DOI: https://doi.org/10.2174/1574885519666230830125139

2023-08-30

Current Drug Therapy

Abstract:Abstract: Multi drug-resistant or extensive drug resistance Mycobacterium tuberculosis poses numerous challenges for health care workers and for public health authorities. Treating multidrug resistant or extensive drug resistance tuberculosis continues to be a difficult task, as a longer regimen is associated with a higher number of adverse drug events and economic burden and has a significant negative effect on health care resources. Many trials and observational studies were conducted. Few studies are underway to develop the universal regimen and improve the outcomes related to multi or extensive drug resistance tuberculosis with a shorter regimen duration. The current review will discuss which drug inhibits what target, their synthesis, genetic aspects, repurposed drugs, novel drugs, and extensive trials for the treatment of multi or extensive drug resistance tuberculosis.
Tuberculosis treatment monitoring tests during routine practice: study design guidance

Emily Lai-Ho MacLean,Alexandra J Zimmer,Saskia den Boon,Ankur Gupta-Wright,Daniela M Cirillo,Frank Cobelens,Stephen H Gillespie,Payam Nahid,Patrick P Phillips,Morten Ruhwald,Claudia M Denkinger,Alexandra J. Zimmer,Daniela M. Cirillo,Stephen H. Gillespie,Patrick P. Phillips,Claudia M. Denkinger

DOI: https://doi.org/10.1016/j.cmi.2023.12.027

IF: 13.31

2024-01-05

Clinical Microbiology and Infection

Abstract:Scope The current tools for tuberculosis (TB) treatment monitoring, smear microscopy and culture, cannot accurately predict poor treatment outcomes. Research into new TB treatment monitoring tools (TMT) is growing, but data are unreliable. In this document, we aim to provide guidance for studies investigating and evaluating TB TMT for use during routine clinical care. Here, a TB TMT would guide treatment during the course of therapy, rather test for cure at the regimen's end. This document does not cover the use of TB TMTs as surrogate endpoints in the clinical trial context. Methods Guidelines were initially informed by experiences during a systematic review of TB TMTs. Subsequently, a small content expert group was consulted for feedback on initial recommendations. After revision, feedback from substantive experts across sectors was sought. Questions addressed by the guideline and Recommendations The proposed considerations and recommendations for studies evaluating TB TMTs for use during treatment in routine clinical care fall into eight domains. We provide specific recommendations regarding study design and recruitment; outcome definitions; reference standards; participant follow-up; clinical setting; study population; treatment regimen reporting; and index tests and data presentation. Overall, TB TMTs should be evaluated in a manner similar to diagnostic tests, but TB TMT accuracy must be assessed at multiple timepoints throughout the treatment course, and TB TMTs should be evaluated in study populations who have already received a diagnosis of TB. Study design and outcome definitions must be aligned with the developmental phase of the TB TMT under evaluation. There is no gold standard for TB treatment response, so different reference standards and comparator tests have been proposed, the selection of which will vary depending on the developmental phase of the TMT under assessment. The use of comparator tests can assist in generating evidence. Clarity is required when reporting of timepoints, TMT read-outs, and analysis results. Implementing these recommendations will lead to higher quality TB TMT studies which will allow data to be meaningfully compared, thereby facilitating the development of novel tools to guide individual TB therapy and improve treatment outcomes.

infectious diseases,microbiology
Perspectivesin CancerResearch Oncogenes , Antioncogenes , and the Molecular Bases of Multistep Carcinogenesis 1

R. Weinberg

Abstract:Tumorigenesis in humans and laboratory animals is a com plex, mu 11Â¡stepprocess (1, 2). In humans, in whom the process has been studied only indirectly, measurements of age-depen dent tumor incidence indicate kinetics dependent on the fifth or sixth power of elapsed time (3). This suggests a succession of five or six independent steps, each of which is rate limiting on the process. In experimental models, such as mouse skin tumorigenesis, the process has been broken down into at least three distinct steps: initiation, promotion, and progression (4, 5). From the perspective of the organism, the multistep nature of tumorigenesis is easily rationalized; each step in the process represents a physiological barrier that must be breached in order for a cell to progress further toward the end point of malignancy. Such multiple barriers conspire to ensure that successful completion of the tumorigenic process is a rarely achieved event. An unanswered question concerns the natures of these bar riers to tumor inception and growth. A portion of the defenses may well derive from systemic defenses against tumors; yet others, confronted in this essay, reflect underlying mechanisms governing the behavior of individual cells. Our cells and likely those of all metazoa would seem to be constructed so as to present multiple impediments to full malignant transformation. Only recently has it been possible to search for the molecular and cellular mechanisms that govern multistep tumorigenesis. What are the rules that govern cell growth? How is the growthregulatory circuitry laid out within the cell? And how can multiple physiological controls be overridden to produce the deregulation of neoplasia?
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs

M Cevik,A Sturdy,A E Maraolo,B G J Dekkers,O W Akkerman,S H Gillespie,J W C Alffenaar

DOI: https://doi.org/10.5588/ijtld.23.0507

2024-09-01

Abstract:<sec><title>OBJECTIVES</title>The coexistence of TB and diabetes mellitus (DM) (TB-DM) is associated with an increased risk of treatment failure, death, delayed culture conversion, and drug resistance. Because plasma concentrations may influence clinical outcomes, we evaluated the evidence on the pharmacokinetic (PK) of TB drugs in individuals with DM to guide management.</sec><sec><title>METHODS</title>We performed a systematic review and meta-analysis through searches of major databases from 1946 to 6 July 2023. PROSPERO (CRD42022323566).</sec><sec><title>RESULTS</title>Of 4,173 potentially relevant articles, we identified 16 studies assessing rifampicin (RIF) PK, 9 on isoniazid (INH), 8 on pyrazinamide (PZA), and 3 on ethambutol (EMB). Two studies reported on second-line anti-TB drugs. According to our meta-analysis, RIF time to maximum concentration (Tmax) was significantly prolonged in patients with DM compared with non-DM patients. We found no significant differences for RIF Cmax, area under the curve (AUC) 0-24 or drug concentration at 2 h (C2h), INH C2h, PZA C2h, PZA Tmax, and EMB Tmax. Although RIF C2h was slightly reduced in patients with TB-DM, this finding was not statistically significant.</sec><sec><title>CONCLUSIONS</title>This review comprehensively examines the impact of DM on the PK of TB drugs. We observed significant heterogeneity among the studies. Given the association between lower plasma concentrations and poor clinical outcomes among patients with DM, we recommend a higher dose limit to compensate for the larger body weight of patients with DM.</sec>.
Antimicrobial therapeutic drug monitoring in critically ill adult patients – An international perspective on access, utilisation, and barriers

Paul Williams,Menino Osbert Cotta,Alexis Tabah,Indy Sandaradura,Salmaan Kanji,Marc H. Scheetz,Sahand Imani,Muhammed Elhadi,Sònia Luque Pardos,Natalie Schellack,Cristina Sanches,Jean Francois Timsit,Jiao Xie,Andras Farkas,Kathryn Wilks,Jason A. Roberts,Alexander Brinkmann,Mahesh Ramanan,Despoina Koulenti,Mohan Gurjar,Helmi Sulaiman,Gentle S. Shrestha,Andrea Cortegiani,Monica Crespo,Lowell Ling,Khalid Abidi,Peter Schellongowski

DOI: https://doi.org/10.1016/j.ijantimicag.2024.107192

IF: 15.441

2024-06-22

International Journal of Antimicrobial Agents

Abstract:Background Therapeutic drug monitoring (TDM) is an effective method for individualising antimicrobial therapy in critically ill patients. The 2021 ADMIN-intensive care unit survey studied a wide range of intensive care unit clinicians worldwide to gain their perspectives on antimicrobial TDM. This article reports the responses from this survey relating to TDM access, utilisation, and barriers. Methods An online survey consisted of multiple-choice questions and 5-point Likert scales. The survey examined respondent's access to minimum inhibitory concentration (MIC) results, drug assays, and dosing software, as well as barriers to TDM. Results The survey included 538 clinicians from 409 hospitals in 45 countries, with 71% physicians and 29% pharmacists. Despite most respondents having access to assays, 21% and 26% of respondents lacked access to vancomycin and aminoglycosides, respectively. In lower-income countries, almost 40% reported no access. Delayed drug assay turnaround time was the most significant barrier to TDM, particularly in lower-income countries. Routine access to MIC results was unavailable for 41% of respondents, with 25% of lower-income country respondents having no access to MIC or susceptibility reports. Conclusions This global survey indicated that consistent TDM usage is hindered by assay access in some sites and the timeliness of assay results in others. Addressing barriers to TDM, particularly in low-income countries, should be a priority to ensure equitable access to affordable TDM.

pharmacology & pharmacy,infectious diseases,microbiology
Therapeutic Drug Monitoring in Anti-Infective Therapy: a Meta-analysis

付双双,唐惠林,段京莉

2013-01-01

Abstract:Objective:To evaluate the effect of therapeutic drug monitoring(TDM)on the clinical efficacy of anti-infective drugs.Methods:Databases were searched including Pubmed,EMbase,The Cochrane Library,CBMDISC and CNKI for random controlled trials and self-controlled studies.For homogeneous studies,meta-analysis was performed to compare the differences in duration of therapy,hospital stay,incidence of nephrotoxicity,total cumulative drug doses and the rate of reaching target concentration between TDM and non-TDM groups.Results:Twenty studies involving 17 755 participants were included.Four studies showed that the duration of vancomycin therapy of TDM group was significantly shorter than non-TDM group.Five studies showed that the hospital stay of the patients treated with aminoglycosides in TDM group was significantly shorter than non-TDM group.Six studies showed that the incidence of nephrotoxicity in TDM group was significantly lower than that of non-TDM group.Six studies showed that the cumulative drug doses of TDM group were not significantly less than that of non-TDM group(P0.05).Five studies showed that the rate of reaching target concentration in patients treated with aminoglycosides in TDM group was significantly higher than that of non-TDM group.Conclusion:TDM can significantly decrease the duration of therapy,hospital stay,incidence of nephrotoxicity and increase the rate of reaching target concentration,which suggests that TDM might be beneficial to achieve better clinical effects.
Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy

Gellert Balazs Karvaly,Barna Vásárhelyi

DOI: https://doi.org/10.3390/pharmaceutics16060792

IF: 6.525

2024-06-12

Pharmaceutics

Abstract:The philosophy, practice, and clinical impact of therapeutic drug monitoring (TDM) has changed profoundly with the appearance of widely available and, in a technical sense, commonly applicable modeling, simulation, and dosing software tools in the past decade [...]

pharmacology & pharmacy
Drug-resistant tuberculosis: a persistent global health concern

Maha Farhat,Helen Cox,Marwan Ghanem,Claudia M. Denkinger,Camilla Rodrigues,Mirna S. Abd El Aziz,Handaa Enkh-Amgalan,Debrah Vambe,Cesar Ugarte-Gil,Jennifer Furin,Madhukar Pai

DOI: https://doi.org/10.1038/s41579-024-01025-1

IF: 88.1

2024-03-24

Nature Reviews Microbiology

Abstract:Drug-resistant tuberculosis (TB) is estimated to cause 13% of all antimicrobial resistance-attributable deaths worldwide and is driven by both ongoing resistance acquisition and person-to-person transmission. Poor outcomes are exacerbated by late diagnosis and inadequate access to effective treatment. Advances in rapid molecular testing have recently improved the diagnosis of TB and drug resistance. Next-generation sequencing of Mycobacterium tuberculosis has increased our understanding of genetic resistance mechanisms and can now detect mutations associated with resistance phenotypes. All-oral, shorter drug regimens that can achieve high cure rates of drug-resistant TB within 6–9 months are now available and recommended but have yet to be scaled to global clinical use. Promising regimens for the prevention of drug-resistant TB among high-risk contacts are supported by early clinical trial data but final results are pending. A person-centred approach is crucial in managing drug-resistant TB to reduce the risk of poor treatment outcomes, side effects, stigma and mental health burden associated with the diagnosis. In this Review, we describe current surveillance of drug-resistant TB and the causes, risk factors and determinants of drug resistance as well as the stigma and mental health considerations associated with it. We discuss recent advances in diagnostics and drug-susceptibility testing and outline the progress in developing better treatment and preventive therapies.

microbiology

Clinical utility of the dexamethasone suppression test assessed by plasma and salivary cortisol determinations

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections

Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009-2014

Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management

Understanding Therapeutic drug monitoring (TDM) at a glance

Alternative Methods for Therapeutic Drug Monitoring and Dose Adjustment of Tuberculosis Treatment in Clinical Settings: A Systematic Review

The past, present and future of tuberculosis treatment.

Manometer extension for high pressure measurement: nuclear quadrupole resonance study of Cu2O with a modified Bridgman anvil cell up to 10 GPa.

A guide to therapeutic drug monitoring of β‐lactam antibiotics

[Low-dose weekly paclitaxel therapy proved useful for a case of recurrent gastric cancer with clinically latent hepatic cirrhosis].

Fixed-dose Combination and Therapeutic Drug Monitoring in Tuberculosis: Friend or Foe?

Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy

Drug targets, current and future therapeutics for the treatment of multi drug resistant tuberculosis with their clinical applications: A critical review

Tuberculosis treatment monitoring tests during routine practice: study design guidance

Perspectivesin CancerResearch Oncogenes , Antioncogenes , and the Molecular Bases of Multistep Carcinogenesis 1

A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs

Antimicrobial therapeutic drug monitoring in critically ill adult patients – An international perspective on access, utilisation, and barriers

Therapeutic Drug Monitoring in Anti-Infective Therapy: a Meta-analysis

Therapeutic Drug Monitoring and Pharmacokinetics-Based Individualization of Drug Therapy

Drug-resistant tuberculosis: a persistent global health concern